Actively Recruiting
Real-World Review of Treatment and Outcomes in Advanced Non-Squamous NSCLC After Platinum Chemotherapy Failure in Brazil
Led by AstraZeneca · Updated on 2026-09-23
250
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a retrospective, noninterventional review of medical records from routine clinical practice to study patients diagnosed with advanced or metastatic non-squamous non-small cell lung cancer NSCLC, either with or without actionable genetic alterations AGA. The study focuses on patients who have failed platinum-based chemotherapy and examines treatment patterns and outcomes following this failure. The research includes subgroup analyses based on specific genetic subtypes such as EGFR, ALK, ROS1, MET1, HER-2, BRAF mutations, and pan-wild-type PD-L1 expression. This observational study reviews records from patients who received at least one line of systemic treatment after failing platinum-based chemotherapy between January 2017 and December 2024. Patients with AGA may have also failed targeted therapies, while those without AGA may have failed immunotherapy after platinum chemotherapy. The analysis covers treatments received before and after the index date, defined as the first dose of any agent following platinum chemotherapy. Participants medical records are reviewed to describe patient populations and treatment patterns during the study period. No interventions or treatments are administered as part of the study. Researchers analyze data collected from routine healthcare to better understand clinical practices and outcomes. The study is led by AstraZeneca and will continue until December 2026.
CONDITIONS
Brief Title
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here